Innate Pharma : Financial visibility out to 2024
>Q1 figures - Innate Pharma this morning reported its sales and its cash position for Q1 2022. Revenues came to € 2.6m and stem mainly from the milestones received in the context of its partnership with AstraZeneca. The cash position at end-March 2022 stands at € 131.7m vs € 159.7m at end-2021. This does not include the milestone payment of $ 50m received from AstraZeneca last April following the dosage of the first patient in the phase III trial evaluating monalizuma...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.